Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Patient Profile 2: Patient Progression After Frontline HCC Therapy

April 8th 2024

Drs Saeed and Shroff discuss the next patient profile, focusing on HCC treatment strategies following disease progression after first-line therapy.

Combining Liver-directed and Systemic Therapies in HCC

April 8th 2024

The impact of compounding liver-directed and systemic therapies in HCC management is discussed by Drs Morse and Covey.

Cadonilimab Plus Oxaliplatin and Capecitabine Offers Survival Benefit in Gastric/GEJ Cancer

April 7th 2024

Cadonilimab plus oxaliplatin and capecitabine leads to survival benefit in gastric/GEJ adenocarcinoma, regardless of PD-L1 expression.

Iglesia Spotlights the Current Complexities of Treatment Sequencing in Advanced HCC

April 5th 2024

Michael Iglesia, MD, PhD, discusses the effects of the phase 3 CELESTIAL trial on treatment sequencing strategies in advanced hepatocellular carcinoma.

Dr Shah on 5-Year Outcomes With Pembrolizumab/Chemo in Esophageal Cancer

April 5th 2024

Manish A. Shah, MD, discusses 5-year outcomes from the KEYNOTE-590 trial of frontline pembrolizumab plus chemotherapy in patients with esophageal cancer.

CAN-2409 Plus Valacyclovir Generates Positive Phase 2 Survival Results in PDAC

April 4th 2024

Positive phase 2 findings for CAN-2409 plus valacyclovir in pancreatic ductal adenocarcinoma have been reported.

FDA to Review Zanidatamab BLA for HER2+ Metastatic Biliary Tract Cancer

April 2nd 2024

A rolling BLA for zanidatamab in previously treated, HER2-positive, advanced biliary tract cancer has been submitted to the FDA.

Dr Pedersen on the Evolution of Immunotherapy in HCC

April 1st 2024

Katrina S. Pedersen, MD, MS, discusses the evolution of the role of immunotherapy in the treatment of patients with hepatocellular carcinoma.

HCC Treatment Strategy Driven by Real-World Evidence

April 1st 2024

Real-world evidence (RWE) provides critical knowledge for providers constructing a treatment regimen for patients diagnosed with hepatocellular carcinoma.

Dr Dotan on Treating Geriatric Patients With Gastroesophageal Cancer

March 29th 2024

Efrat Dotan, MD, discusses a retrospective study aiming to understand the needs of geriatric patients with gastroesophageal cancer.

Leveraging Immunotherapy in GI Malignancies: Looking to the Future

March 29th 2024

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.

Leveraging Immunotherapy in GI Malignancies: Research, Including Organoids and Ablation

March 29th 2024

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss research efforts being made with organoids to address existing questions with immunotherapy and the exploration of multimodality approaches to improve outcomes.

Leveraging Immunotherapy in GI Malignancies: A Shift in Drug Discovery

March 29th 2024

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss the potential benefits of utilizing immunotherapy approaches earlier on in the disease course.

Leveraging Immunotherapy in GI Malignancies: Assays for Early Detection and Prevention

March 29th 2024

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts explain the challenges faced with preventing or detecting these cancers early and the understanding needed to develop effective early detection methods and move the needle forward.

Leveraging Immunotherapy in GI Malignancies: Is Multicancer Early Detection Becoming a Reality?

March 29th 2024

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.

Dr Sahin on the Utility of the Northstar Response Assay in GI Cancer

March 28th 2024

Ilyas Sahin, MD, discusses the potential utility of Northstar Response assay in patients with advanced gastrointestinal cancer.

Navigating First-Line Treatment Options in Advanced, Unresectable HCC

March 26th 2024

Pierre Gholam, MD, discusses primary considerations for the first-line treatment of patients with advanced, unresectable HCC.

Japan’s MHLW Approves Zolbetuximab in CLDN18.2-Positive Gastric Cancer

March 26th 2024

The Japanese Ministry of Health, Labour and Welfare has approved zolbetuximab for CLDN18.2-positive, unresectable, advanced or recurrent gastric cancer.

IMBrave150 Study Overview

March 25th 2024

Dr Gong breaks down the structure and key takeaways from the IMBrave150 study.

Establishing Optimal HCC Treatment Strategy

March 25th 2024

Anwaar Saeed, MD, provides comprehensive insight into the HCC treatment selection process.